In the case of FGFRs, the presence of activating gene mutations in the FGFR axis, of various forms, has been reported in up to 18% of breast cancers, including FGFR1 and FGFR2 amplifications, point mutations in the ligand-binding region and oncogenic fusion proteins [104]. This evidence concerns the gene FGFR2 and breast cancer.